Abstract

Obstructive Sleep Apnea (OSA) is a prevalent condition and a major cause of morbidity and mortality in Western Society. The loss of motor input to the tongue and specifically to the genioglossus muscle during sleep is associated with pharyngeal collapsibility and the development of OSA. We applied a novel chemogenetic method to develop a mouse model of sleep disordered breathing Our goal was to reversibly silence neuromotor input to the genioglossal muscle using an adeno-associated viral vector carrying inhibitory designer receptors exclusively activated by designer drugs AAV5-hM4Di-mCherry (DREADD), which was delivered bilaterally to the hypoglossal nucleus in fifteen C57BL/6J mice. In the in vivo experiment, 4 weeks after the viral administration mice were injected with a DREADD ligand clozapine-N-oxide (CNO, i.p., 1mg/kg) or saline followed by a sleep study; a week later treatments were alternated and a second sleep study was performed. Inspiratory flow limitation was recognized by the presence of a plateau in mid-respiratory flow; oxyhemoglobin desaturations were defined as desaturations >4% from baseline. In the in vitro electrophysiology experiment, four males and three females of 5 days of age were used. Sixteen–nineteen days after DREADD injection brain slices of medulla were prepared and individual hypoglossal motoneurons were recorded before and after CNO application. Positive mCherry staining was detected in the hypoglossal nucleus in all mice confirming successful targeting. In sleep studies, CNO markedly increased the frequency of flow limitation n NREM sleep (from 1.9 ± 1.3% after vehicle injection to 14.2 ± 3.4% after CNO, p < 0.05) and REM sleep (from 22.3% ± 4.1% to 30.9 ± 4.6%, respectively, p < 0.05) compared to saline treatment, but there was no significant oxyhemoglobin desaturation or sleep fragmentation. Electrophysiology recording in brain slices showed that CNO inhibited firing frequency of DREADD-containing hypoglossal motoneurons. We conclude that chemogenetic approach allows to silence hypoglossal motoneurons in mice, which leads to sleep disordered breathing manifested by inspiratory flow limitation during NREM and REM sleep without oxyhemoglobin desaturation or sleep fragmentation. Other co-morbid factors, such as compromised upper airway anatomy, may be needed to achieve recurrent pharyngeal obstruction observed in OSA.

Highlights

  • Obstructive sleep apnea (OSA) is due to recurrent closure of upper airway during sleep leading to intermittent hypoxia and fragmentation of sleep [1]

  • In this study we explored whether inhibition of hypoglossal motoneurons may lead to sleep disordered breathing even in the absence of the compromised upper airway anatomy

  • We examined whether chemogenetic inhibition of hypoglossal motoneurons would lead to sleep disordered breathing in lean C57BL/6J mice

Read more

Summary

Introduction

Obstructive sleep apnea (OSA) is due to recurrent closure of upper airway during sleep leading to intermittent hypoxia and fragmentation of sleep [1]. OSA is a common disease affecting ≥30% of the adult population [2]. OSA predisposes to motor vehicle and industrial accidents and contributes significantly to the development and progression of neurocognitive, metabolic, cardiovascular, and oncologic diseases [2,3,4,5,6,7]. Nasal continuous positive airway pressure (CPAP) relieves upper airway obstruction during sleep but does not reverse underlying defects in pharyngeal collapsibility. There is no effective pharmacotherapy for OSA [9,10,11]. The creation of an adequate rodent model that mimics human OSA would facilitate the progress in the field

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call